NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered ...
Summary: The non-animal alternative testing market is being driven by several factors, including increasing awareness and concern over animal welfare, a growing focus on the development of non-animal ...
Physicians may one day be able to identify which patients with peripheral artery disease are most likely to develop ...
Interesting Engineering on MSN
New coating test improves conductivity of lithium-ion batteries in under 5 minutes
Scientists in Japan have developed a new way to monitor lithium-ion battery slurries during ...
SHENZHEN, GUANGDONG, CHINA, May 14, 2026 / EINPresswire.com / — ...
Updated positive data from iadademstat in 1L AML unfit patients to be presented at EHA, with 100% ORR, 93% CRc and 79% strict CR at abstract ...
Artificial intelligence shows promise for improving care for peripheral artery disease through earlier detection, improved ...
While GenAI reacts to prompts or triggers to create content, agentic AI is intended to autonomously establish and control a ...
Discover how robust screening assays enhance data quality and reliability in high-throughput screening for drug discovery.
University of Michigan leaders explain how M Air aims to connect drones, AAM, and Detroit’s automotive manufacturing ecosystem.
The legal architecture for AI governance is no longer about policy adoption but about whether an organization can produce evidence that traces ...
NAMs may enable faster identification of emerging swine viruses, improve understanding of virus-host interactions, and help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results